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Abstract
Objective: Several studies have shown that there is an upward shift in the classification of cervical cytology when high-risk
human papillomavirus (hrHPV) status is known to be positive. The Netherlands implemented primary hrHPV screening with
reflex cytology as the primary screening test in 2017. Prior to implementation of the new programme, we investigated whether
knowledge of hrHPV status influences cytology rating.
Methods: Using a set of 200 cytology slides that had been previously tested, two pairs of cytotechnicians rated 100 slides per
pair twice: first without knowledge of hrHPV status and then, after a wash-out period of two months, with knowledge of
hrHPV status.
Results: We found that hrHPV positive slides were more likely to be rated up over the referral threshold (i.e. from negative
for intraepithelial lesion or malignancy to atypical squamous cells of undetermined significanceþ) than hrHPV negative slides at
the second review when hrHPV status was known (relative risk¼ 3.2; 95% confidence interval: 1.3–7.9).
Conclusions: If the same upward shift in ratings were to be observed in the national programme, it may have implications for
referrals of women with low-grade lesions.
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Introduction
In 2017, the Netherlands replaced primary cytology with
primary high-risk Human Papillomavirus (hrHPV) screen-
ing in the national cervical cancer screening programme. All
eligible women (aged 30–60) are offered hrHPV screening
every five years, with reflex cytology when hrHPV is found.
Several studies have found that knowledge of positive HPV
status can result in upward rating of cervical cytology.1–6 In
the renewed Dutch programme, all cytology slides reviewed
will be hrHPV positive. An upward shift in cytology rating
may result in more referrals. We aimed to investigate
whether cytotechnicians would classify cytology slides
higher when positive hrHPV status is known.
Methods
A set of 200 unmarked glass slides (50% hrHPV posi-
tive), taken between August 2013 and July 2014 and
adjusted for age and expected proportion of cytological
abnormalities was selected from the Dutch screening com-
parison study (DuSC).7 This set was divided into two sets
of 100, each allocated to a pair of cytotechnicians
for review.
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Four experienced cytotechnicians volunteered for this
study and were grouped into two pairs. Prior to the imple-
mentation of the hrHPV screening programme, each pair
reviewed 100 slides twice: once without hrHPV status, and
after a two-month wash-out, with hrHPV status and reor-
dered slides. Analysts were asked to rate slides in one of
the following categories (equivalent Bethesda classification
shown in brackets):
• Pap 0 (Inadequate quality)
• Pap 1 (Negative for intraepithelial lesion or malignan-
cy (NILM))
• Pap 2 (Atypical squamous cells of undetermined signif-
icance (ASC-US))
• Pap 3a1 (Low-grade squamous intraepithelial
lesion (LSIL))
• Pap 3a2 (High-grade squamous intraepithelial
lesion (HSIL))
• Pap 3b (HSIL)
• Pap 4 (Carcinoma in situ or worse)
There were 800 individual observations from the entire
dataset; 400 observations from each review (100 paired
observations per cytotechnician). Twenty slides (10% of
sample; 9 hrHPV positive, 11 hrHPV negative) were
excluded due to the incorrect hrHPV status being acciden-
tally provided at the second review, resulting in 360 paired
observations from 180 slides. Switches in rating between
review 1 and 2 were classified as upgrades (e.g. NILM to
ASC-US), downgrades (e.g. LSIL to NILM), no
change (e.g. NILM at both ratings) or to/from inadequate.
Ratings from NILM to ASC-USþ or vice versa were
classified as switches over or below the referral threshold.
The net increase/decrease in referrals was calculated
by subtracting the number of upgrades over the
referral threshold at the second review from the number
of downgrades below the referral threshold at the
second review.
Data analysis was performed using SAS Base 9.4 and
IBM SPSS Statistics v25. The highest classification was
selected for three records categorized in multiple categories
(e.g. ‘Pap 0/1’). Risk estimates were calculated.
Proportional risk difference was calculated using Wald
asymptotic test of equality. Wald asymptotic confidence
limits were calculated for proportions.
Results
HrHPV positive slides were more likely to be upgraded
over the referral threshold at the second review than
hrHPV negative slides (relative risk (RR)¼ 3.2; 95% con-
fidence interval (CI): 1.3%–7.9%). There was a net
increase in ratings that would result in referral between
the first and second review of 12 for hrHPV positive
slides and a net decrease of 18 for hrHPV negative
slides. Overall, hrHPV negative slides were downgraded
29 times (15.9%; 95% CI: 10.6%–21.3%), compared
with 15 times (8.4%; 95% CI: 4.3%–12.5%) for hrHPV
positive slides (p¼ 0.03). Conversely, hrHPV positive
slides were upgraded 22 times (12.4%; 95% CI: 7.8%–
17.2%), compared with seven times (3.8%; 95% CI:
1.0%–6.7%) for hrHPV negative slides (p¼ 0.003).
Results by Bethesda classification are shown in Figure 1.
Discussion
This study suggests that there may be an upward shift in
the rating of cervical cytology slides when positive hrHPV
status is known. Our results show that hrHPV positive
slides were rated upwards more often than hrHPV nega-
tive slides, and more often over the referral threshold. This
is consistent with previous literature.3,4 Upgrading cytolo-
gy when hrHPV status is positive was previously observed
in Dutch observational data. Between 2007 and 2016,
hrHPV testing was used in some laboratories, as an addi-
tional test at six months for women with ASC-US/LSIL at
primary screening. Under this policy, significantly fewer
slides were rated NILM, and significantly more slides
were rated ASC-US/LSIL at six-month follow-up when
hrHPV status was known.8 Similar results were also seen
in the regular monitoring of the Dutch national screening
programme, with more slides rated at ASC-US or higher
when hrHPV testing was performed at six-month
follow-up.9
Two studies1,2 found that prior knowledge of hrHPV
status resulted in an increased sensitivity for CIN 2þ
lesions, which points to an increase in true positive refer-
rals. However, first results of the new hrHPV screening
programme show both increased CIN 2þ detection and
more unnecessary referrals (<CIN 2) compared with the
cytology-based programme,10 suggesting that there may be
an influence of upward cytology ratings on the number of
referrals of women with low-grade lesions. As all women
with hrHPV positive, ASC-US+ primary screens are
directly referred in the new hrHPV-based programme, an
increase in slides rated as ASC-US may lead to more
women with low-grade lesions being referred unnecessari-
ly. This is concerning, as overtreatment of low-grade
lesions also presents risks of harm. To mitigate the
impact of potential cytology upgrading within the Dutch
programme, training was provided at all five screening
programme laboratories on morphological differences
between Pap classifications (Personal Communication, 28
February 2018), and professional education continues to
be provided.
This study has several strengths. Because this study was
conducted prior to implementation of the new hrHPV
screening programme, cytotechnicians were still reviewing
both hrHPV positive and negative slides. The cytotechni-
cians in this study were experienced in evaluating cervical
cytology. The distribution of age and abnormalities
reflects the screened population, as slides were drawn
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from the screening programme. The study also has some
limitations. The small sample size has an impact on statis-
tical power. Additionally, 10% of slides were excluded,
due to incorrect HPV status provided at the second review.
Conclusion
Our study suggests that knowledge of hrHPV status may
result in an upward shift in cytology ratings. While appro-
priate training is being provided to cytotechnicians,
continued monitoring of unnecessary referrals will be
essential, to mitigate risks of overtreatment following
referrals of women with low-grade lesions.
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arrows represent downgrades. Solid grey arrows represent changes to or from ‘inadequate’. Numbers in the figure represent pairs of
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